MLAB 1227- Coagulation Keri Brophy-Martinez - PowerPoint PPT Presentation

1 / 17
About This Presentation
Title:

MLAB 1227- Coagulation Keri Brophy-Martinez

Description:

MLAB 1227- Coagulation Keri Brophy-Martinez Fibrinolytic System * * * * * * * Fibrinolysis Process of removing fibrin from the vasculature Key Players Plasminogen ... – PowerPoint PPT presentation

Number of Views:196
Avg rating:3.0/5.0
Slides: 18
Provided by: Keri84
Category:

less

Transcript and Presenter's Notes

Title: MLAB 1227- Coagulation Keri Brophy-Martinez


1
MLAB 1227- CoagulationKeri Brophy-Martinez
  • Fibrinolytic System

2
Fibrinolysis
  • Process of removing fibrin from the vasculature
  • Key Players
  • Plasminogen
  • Plasminogen activators (PA)
  • Active enzyme plasmin (PLN)
  • Fibrin
  • Fibrin/Fibrinogen degradation products
  • Inhibitors of plasminogen activators and PLN

3
Fibrinolytic System
  • Sensitive to imbalances
  • Restricts fibrin formation to area of injury
  • Initiated when coagulation cascade begins
  • Dissolves clot by digestion of fibrin

4
Overview
  • Under the influence of thrombin.
  • Fibrinogen cleaved into fibrin monomers
  • Fibrin monomers are cleaved into fibrin
    degradation products or fibrin split products

5
Process summary
  • Once clotting begins, the fibrinolytic system
    comes to life
  • Plasminogen (PLG) binds to fibrin in the
    developing thrombus
  • Tissue-type PLG activator (tPA) also binds to
    fibrin, increasing its enzymatic activity to
    convert plasminogen to plasmin (PLN)
  • Complex formation of tPA, PLG and fibrin results
    in the break-down of fibrin
  • PLN then further digest fibrin to soluble
    degradation products making fibrin fragments

6
Plasminogen
  • Produced in the liver
  • Found in normal plasma
  • Following injury, binds to fibrin during clot
    formation along with plasminogen activators

7
Activators of Fibrinolysis
  • Contact Phase/Intrinsic
  • Occurs by interactions of the contact factors
    (XIIa, HMWK, and PK) following intrinsic pathway
    activation(collagen exposure)
  • Physiologic
  • Activators released from tissues extrinsic to the
    blood
  • tPA tissue- type PLG activator
  • Found in endothelial cells of small vessels
  • uPA urokinase-type PLG activator
  • Made in renal tubular epithelium and vascular
    epithelium
  • Found in urine and plasma
  • Exogenous activation
  • Via medications given to lyse pathogenic clots
    (i.e. pulmonary emboli)
  • Example includes Streptokinase

8
Activators
9
Plasmin
  • Proteolytic enzyme
  • Dissolves fibrin/fibrinogen clots into protein
    fragments that are cleared from plasma by the
    liver
  • Provides a positive feedback loop for forming
    more plasminogen
  • Highly regulated
  • Temporarily active
  • Local

10
Fibrinogen and Fibrin
  • Fibrin degradation products are the protein
    fragments of fibrin or fibrinogen.
  • The protein fragments are designated X, Y, D, and
    E
  • Fragments are strong inhibitors of further
    coagulation by
  • interfering with the action of thrombin
  • interfering with platelet aggregation
  • In the lab, referred to as FDPs or FSPs
  • Fibrin degradation products are cleared by the
    liver
  • Fibrinogen and fibrin yield essentially the same
    fragments however degradation of cross-linked
    fibrin is slower and leads to fragments that
    contain D-dimer.

11
Plasmin Degradation of Fibrinogen

E
Fibrinogen
D
D
plasmin
E
D
D
Fragment X small peptides from carboxyl end of a
chain removed
plasmin
E
Fragment Y Fragment D
D
D
plasmin
E
D
Fragment D Fragment E
12
  • Plasminogen
  • Intrinsic/contact activation
    Physiologic activation

  • Exogenous activation
  • Plasmin
  • Fibrin clot Fibrinogen
  • Fibrin
  • Degradation Fibrinogen
  • Products Degradation
  • Products
  • X,Y,DD,E X,Y,D,E,D

13
Inhibitors of Fibrinolysis
  • Used to regulate and limit plasmin activity and
    fibrinolysis
  • Also referred to as an antiplasmin
  • How?
  • Target PLG activation step
  • Target plasmin

14
Inhibitors of Fibrinolysis
Inhibitors
Inhibitors
15
Specific Inhibitors
  • Plasminogen Activator Inhibitor (PAI)
  • PAI-1 most significant
  • Inhibits tPA and uPA
  • Acute phase reactant protein
  • Thrombin Activatable Fibrinolysis Inhibitor
    (TAFI)
  • Eliminates fibrin binding sites for plasminogen

16
Specific Inhibitors
  • alpha-2-antiplasmin
  • Rapid inhibitor of plasmin
  • Functions to catch leaked PLN in the
    circulation, thus limiting activity to fibrin
    clot
  • Produced in liver and a granules in platelets
  • alpha-2-macroglobulin
  • Slower inhibitor of plasmin

17
References
  • McKenzie, Shirlyn B., and J. Lynne. Williams.
    "Chapter 30." Clinical Laboratory Hematology.
    Boston Pearson, 2010. Print.
Write a Comment
User Comments (0)
About PowerShow.com